Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 4 of a 4-Part Series
Hematologic Oncology Update
00:00
CAR T Therapy in a 66 Year Old Female Quad Refractory Patient
A 66 year old female quad refractory. She's asymptomatic. This patient's had numerous serious infectious issues. The question is where is the optimal place for these medications to be given? May they be given in the academic center first and then come back into the community? So these are new class of drugs that seem incredibly effective. And then with by specifics, what is the ultimate role of CAR T therapy going to be?
Transcript
Play full episode
